Novo Buys Alkermes Manufacturing Facility for Oral Assets; Fractyl Announces New Revita Analysis; AZ Initiates Ph2 Oral PCSK9i Study in Dyslipidemia; Nexletol/Nexlizet Label Updates
Here is a brief preview of this blast: Four cardiometabolic-related news items have been observed from Novo/Alkermes, Fractyl, AZ, and Esperion. Below, FENIX provides highlights and insights into the respective news items.